
EHDS – Be prepared for public consultations in TEHDAS2:
**Draft guideline for Health Data Access Bodies on minimum categories and
limitations on the reuse of health data**

Sebastian C. Semler, TMF e. V. &
Dr. Anna Niemeyer, TMF e. V.
September 15th, 2025 | 8 a.m. to 9 a.m.

online workshop series | September 15th to October 1st, 2025



Welcome & Introduction


1. EHDS and TEHDAS2 in a nutshell
2. TEHDAS2 Documents for public consultation on September 30th, 2025
3. Presenting today's document:
Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data
 - 3.1 Legal background
 - 3.2 Summary of the document
 - 3.3 Critical points
 - 3.4 Who should comment?
4. Q&A
5. Save the date: Next workshops

1. EHDS and TEHDAS2 in a nutshell

European Health Data Space (EHDS) – AIMS FROM User perspectives


Primary use (routine care)

Secondary use



1. EHDS and TEHDAS2 in a nutshell

EHDS2: Secondary Use of Electronic Health Data



- ▶ Das Europäische Parlament hat am 24. April 2024 die legislativen Grundlagen zur Schaffung eines **Europäischen Gesundheitsdatenraums (EHDS)** gelegt.
- ▶ Sprachjuristische Endfassung, vom ER am 21.01.2025 verabschiedet.
- ▶ Die EHDS-Verordnung wurde am 5. März 2025 im Amtsblatt der EU veröffentlicht **und trat 20 Tage später, am 25. März 2025, in Kraft.**
- ▶ Die Vorschriften der EHDS-Verordnung werden schrittweise angewendet: teilweise nach zwei Jahren, teilweise nach vier, sechs oder zehn Jahren nach Inkrafttreten. Direkt rechtswirksam in allen EU-Mitgliedstaaten, so auch in Deutschland.
- ▶ **MyHealth@EU (EHDS I)** regelt **elektronische grenzüberschreitende Gesundheitsdienste** in der EU (und die hierfür notwendigen Voraussetzungen).
- ▶ Im Rahmen von **HealthData@EU (EHDS II)** soll das Potenzial der **(Sekundär-)Nutzung von vorhandenen Gesundheitsdaten für Forschung und Innovation** in anonymisierter oder pseudonymisierter Form im öffentlichen Interesse erschlossen werden.
- ▶ ➔ Detailierung durch **Durchsetzungsrechtsakte (Implementing Acts)** bis 26. März 2027



European
Union

EUR-Lex

Access to European Union law

<https://eur-lex.europa.eu/legal-content/DE/TXT/?uri=CELEX%3A32025R0327&qid=1741704307107>



My EUR-Lex



English



Experimental features



EUROPA > EUR-Lex home > Verordnung - EU - 2025/327 - EN - EUR-Lex

Help

Print

Share

MENU

QUICK SEARCH



Search tips

Need more search options? Use the [Advanced search](#)

Document 32025R0327

Verordnung (EU) 2025/327 des Europäischen Parlaments und des Rates vom 11. Februar 2025 über den europäischen Gesundheitsdatenraum sowie zur Änderung der Richtlinie 2011/24/EU und der Verordnung (EU) 2024/2847 (Text von Bedeutung für den EWR)

PE/76/2024/REV/1

AbL. L, 2025/327, 5.3.2025, ELI: <http://data.europa.eu/eli/reg/2025/327/oj> (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

In force

ELI: <http://data.europa.eu/eli/reg/2025/327/oj>

Expand all Collapse all

Languages, formats and authentic version

	BG	ES	CS	DA	DE	ET	EL	EN	FR	GA	HR	IT	LV	LT	HU	MT	NL	PL	PT	RO	SK	SL	FI	SV
HTML																								
PDF - authentic OJ																								
e-signature																								

How to verify the authenticity of the Official Journal

Multilingual display

English (en) ▾

Please choose ▾

Please choose ▾

Display

Text

Text

Document information

Procedure

Up-to-date link

Permanent link

Download notice


Save to My items

Create an email alert

Create an RSS alert

Table of contents

EHDS – Inkrafttreten und Geltung




1. TEHDAS2 in a nutshell

TEHDAS2 in a nutshell

- 1 A joint action with clear scope, timeline and budget
- 2 Structured in independent work packages but common working methods
- 3 Aims for harmonised implementation of EHDS – secondary use of health data
- 4 Produces tangible results in the form of guidelines and technical specifications
- 5 High emphasis also on external communication and interlinks with other projects

für Deutschland: **BMG, BfArM, gematik, TMF**

- ▶ TEHDAS2 bereitet die Durchsetzungsrechtsakte der EU zum EHDS II durch **Guidelines** vor.
- ▶ (Für EHDS I entsprechend: xt-EHR)
- ▶ in 3 „Wellen“ (1. bereits erfolgt)
- ▶ Die Guidelines werden vor Verabschiedung und Annahme durch die EU öffentlich zur Kommentierung gestellt. Beginn: 30. Sept. 2025 (2 Monate)



2. TEHDAS2 Guidelines



Upcoming public consultations

SEP-OCT 2025

TOPIC: Processes to manage permits or data pseudonymisation

Documents scheduled for public consultation(Click to view)

1. Draft guideline for Health Data Access Bodies on fees and penalties for non-compliance regulated to the EHDS regulation
2. Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data
3. Draft guideline for data holders on making personal and non-personal electronic health data available for reuse
4. Draft guideline for Health Data Access Bodies on the procedures and formats for data access
5. Data Access Application Management System (DAAMS) – Draft technical specification for health data access bodies
6. Draft technical specification for Health Data Access Bodies on data minimisation and de-identification
7. Draft technical specification for Health Data Access Bodies on the implementation of the common IT infrastructure
8. Draft technical specification for Health Data Access Bodies on the implementation of secure processing environments
9. Draft guideline for Health Data Access Bodies on implementing opt-out from the secondary use of health data
10. Draft guideline for Health Data Access Bodies on implementing the obligation of notifying the natural person on a significant finding from the secondary use of health data

<https://tehdas.eu/>



MAY-JUN 2026

TOPIC: Collaboration with third countries, data enrichment and informing citizens

Documents scheduled for public consultation(Click to view)

1. Draft guideline for Health Data Access Bodies on collaboration with other parties
2. Draft guideline for Health Data Access Bodies on international and third country access and transfer of electronic health data
3. Draft guideline for Health Data Access Bodies on enrichment of health datasets
4. Draft guideline for Health Data Access Bodies on linkage of health datasets
5. Draft guideline for Health Data Access Bodies on informing natural persons about the use of health data – “Citizen Information Point”
6. Draft guideline for data users on handling research outcomes

2. TEHDAS2 Participate in the public consultations



TEHDAS2 develops guidelines and technical specifications to enable seamless secondary use of electronic health data across Europe under the European Health Data Space (EHDS).



→ The next wave of public consultations will be in **Sept-Oct 2025**

2. TEHDAS2 Documents for public consultation on September 30th, 2025



2nd Wave: Processes to manage permits or data pseudonymisation | SEP-OKT 2025

MS/D	Description
4.1	Draft guideline for Health Data Access Bodies on fees and penalties for non-compliance related to the EHDS regulation
5.2	Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data
6.1	Draft guideline for data holders on making personal and non-personal electronic health data available for reuse
6.3	Draft guideline for Health Data Access Bodies on the procedures and formats for data access
6.4	Data Access Application Management System (DAAMS) – Draft technical specification for health data access bodies
7.2	Guideline for Health Data Access Bodies on data minimisation, pseudonymisation, anonymisation and synthetic data
7.3	Draft technical specification for Health Data Access Bodies on the implementation of the common IT infrastructure
7.4	Draft technical specification for Health Data Access Bodies on the implementation of secure processing environments
8.1	Draft guideline for Health Data Access Bodies on implementing opt-out from the secondary use of health data
8.1	Draft guideline for Health Data Access Bodies on implementing the obligation of notifying the natural person on a significant finding from the secondary use of health data

3. Presenting today's document: **Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data (5.2)**



3.1 Legal background

Based on Chapter IV of the European Health Data Space Regulation (EHDS, EU 2025/327),

Article 53 – exhaustively lists six **permitted purposes for secondary use** of electronic health data, including public interest, policymaking, statistics, education, scientific research, and healthcare improvement, while

Article 54 – specifies **strictly prohibited secondary uses** such as discrimination, marketing, development of harmful products, and violations of national ethical rules. In addition,

Article 52(3) – sets limitations regarding data availability due to **unresolved intellectual property rights** (IPR) or **trade secret concerns**.

The guideline also ties these legal references to the **relevant GDPR provisions**, notably Article 6 and 9 for lawful processing and Recital 61 for a broad interpretation of scientific research

3. Presenting today's document: **Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data (5.2)**




3.2 Summary of the document

The document provides practical guidance for HDABs to ensure consistent, lawful, and ethical processing of health data access applications.

It describes:

- The six permitted **secondary use purposes (Article 53)** and explains the institutional eligibility, documentation, and required clarifications for each category.
- The **assessment process**, emphasizing detailed scrutiny of application narratives, verification of applicant mandates, and analysis of purpose versus institutional affiliation.
- Concrete recommendations on **operational procedures for HDABs**, including investigation, documentation, collaboration, and the need for legal and ethical support systems.
- A comprehensive review of **prohibited uses under Article 54**, highlighting risks such as discrimination, marketing, and development of harmful products, while providing real-world examples and red flags.
- Guidelines for **handling IPR** and **trade secret limitations**, including best practice suggestions for protection mechanisms and documentation requirements.
- Areas for further discussion including **harmonisation among member states**, clarity between innovation and marketing, the ambiguous licensing of controlled substances in research, and monitoring systems for misuse.

Purposes for secondary use & prohibited secondary uses



3. Presenting today's document: **Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data (5.2)**



3.3 Critical points

Several critical aspects and unresolved issues are identified throughout the guideline:

- **Ambiguity in the definitions** of key concepts such as “public interest,” “scientific research,” and
- **Boundaries between innovation and marketing**, which may result in inconsistent implementation across member states.
- The **challenge in reliably detecting and preventing prohibited secondary uses** (e.g., discrimination, marketing) due to **difficulty in monitoring** downstream data use and vague or non-transparent project objectives.
- **Diversity in national ethical requirements and practices**, creating complexities for HDABs and data applicants in multi-country contexts.
- The **lack of harmonised European standards** for assessment, documentation, and ongoing monitoring, leading to governance gaps in quality and consistency.
- Unresolved questions regarding the **extent and enforcement of IPR/trade secret protection**, and the need for regular reviews and updates to the guideline in light of experience and evolving legal interpretation

3. Presenting today's document: **Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data (5.2)**



3.4 Who should comment?

The document explicitly identifies several stakeholder groups who should provide feedback and be involved in its refinement:

- **Health Data Access Bodies (HDABs)** from all member states, as primary users of the guideline.
- **Health data holders** (e.g., hospitals, registries), since their collaboration is essential for clarifying datasets and IPR concerns.
- **Data applicants** (e.g., researchers, public authorities, life-science companies), who face practical challenges in fulfilling documentation and process requirements.
- **National and European ethics bodies, legal experts, and advisory boards**, needed for resolving institutional, technical, and ethical questions.
- **Policymakers and IT implementers** involved in the operationalisation and monitoring of EHDS procedures.
- **Community of Practice structures (HDABs CoP), EHDS Board subgroups, and DG SANTÉ** for ongoing governance and annual updates.

4. Q&A



2. TEHDAS2 Online-Workshop-Serie 15.09.-01.10.2025



Date	Workshop
Sep 15th, 2025	5.2 Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data, <i>Dr. Anna Niemeyer (TMF e. V., Germany)</i>
Sep 16th, 2025	8.1.1: Draft guideline for Health Data Access Bodies on implementing opt-out from the secondary use of health data, <i>Irene Schlünder (TMF e. V., Germany)</i>
Sep 17th, 2025	7.2: Draft guideline for Health Data Access Bodies on data minimisation, pseudonymisation, anonymisation and synthetic data, <i>Pia Brinkmann (Bundesinstitut für Arzneimittel und Medizinprodukte BfArM, Germany)</i>
Sep 18th, 2025	6.1: Draft guideline for data holders on making personal and non-personal electronic health data available for reuse, <i>Marije van Melle (Nictiz, Netherlands)</i>
Sep 24th, 2025	6.3: Draft guideline for Health Data Access Bodies on the procedures and formats for data access, <i>Rosa Jutii (Findata, Finland)</i>
Sep 25th, 2025	6.4: Draft Data Access Application Management System (DAAMS) – Draft technical specification for health data access bodies, <i>Dr. Ana Mužinić, Ph.D (Bundesinstitut für Arzneimittel und Medizinprodukte BfArM, Germany)</i>
Sep 26th, 2025	7.3: Draft technical specification for Health Data Access Bodies on the implementation of the common IT infrastructure, <i>Amélie Schäfer (Health Data Hub, France)</i>
Sep 29th, 2025	7.4: Draft technical specification for Health Data Access Bodies on the implementation of secure processing environments, <i>Heikki Lehväslaihi (CSC - IT Center for Science, Finland)</i>
Sep 30th, 2025	8.1.2: Draft guideline for Health Data Access Bodies on implementing the obligation of notifying the natural person on a significant finding from the secondary use of health data, <i>Dr. Gergely Mikešy (Semmelweis University Health Services Management Training Centre, Hungary)</i>
Oct 1st, 2025	4.1: Draft guideline for Health Data Access Bodies on fees and penalties for non-compliance related to the EHDS regulation, <i>Pia Brinkmann (Bundesinstitut für Arzneimittel und Medizinprodukte BfArM, Germany)</i>

Mehr Information & Anmeldung: <https://www.tmf-ev.de/news/ehds-oeffentliche-konsultationen-starten-im-herbst>

Contact

TMF e. V.
Charlottenstraße 42/Dorotheenstraße
10117 Berlin

www.tmf-ev.de | [@TMF_eV](https://twitter.com/TMF_eV)

Dr. Anna Niemeyer
+49 30 22 00 24 764
anna.niemeyer@tmf-ev.de

Irene Schlünder
+49 30 22 00 24 742
irene.schluender@tmf-ev.de